We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Next-Gen Sequencing Method Predicts Prostate Cancer Risks

By LabMedica International staff writers
Posted on 08 Jan 2019
Print article
Image: A comparison of OncoScan array CGH assay–derived metastasis potential scores (MPSs) for indolent primary tumor (iPT) and metastasis-prone primary tumor (mPT) samples (Photo courtesy of Albert Einstein College of Medicine).
Image: A comparison of OncoScan array CGH assay–derived metastasis potential scores (MPSs) for indolent primary tumor (iPT) and metastasis-prone primary tumor (mPT) samples (Photo courtesy of Albert Einstein College of Medicine).
Prostate cancer is the most commonly diagnosed male cancer and the second leading cause of cancer deaths among men in the USA, with approximately 220,000 new diagnoses and approximately 27,000 deaths each year.

Men with clinical low-risk disease can receive active surveillance to safely preserve quality of life, provided that the risk of an undetected aggressive cancer can be managed. Clinical tests for the prognosis of prostate cancer from radical prostatectomy specimens and biopsy specimens are being increasingly used to inform treatment and active surveillance protocols.

A team of scientists led by those at the Albert Einstein College of Medicine (Bronx, NY, USA) collected from prostate cancer radical prostatectomy cohort of 72 men was collected at Duke University. A total of 88 prostate cancer surgical research (PCSR) samples (from 69 unique men) and 21 healthy samples were microdissected and underwent DNA extraction. A second prostate cancer cohort comprised 12 PCSR samples with matched punched biopsy samples (Duke Cohort 2). All PCSR samples (Duke Cohorts 1 and 2) were assayed on the OncoScan formalin-fixed, paraffin-embedded (FFPE) version 3 array and on the Next Generation Copy Number Alteration NG-CNA panel.

The team developed a genomic DNA signature, the metastatic potential score (MPS), and verified it as highly predictive of prostate cancer, triple-negative breast cancer, and lung adenocarcinoma metastases using surgical samples. Metastases and metastasis-prone primary tumors demonstrated enrichment of specific CNAs in one direction, either gain or loss. This directionality provided a basis for calculating scores for the specific genes within the CNA regions that included a penalty when the CNA went against the expected directionality.

The team reported that the NG-CAN assay can analyze 902 genomic sites across 194 genomic regions, which it can do both faster than existing tests and at a lower cost. With the NG-CNA, the cost of DNA extraction, library preparation, and sequencing reagents can be USD 20 to USD 40 per sample, compared to nearly USD 1,000 for whole genome sequencing. The team noted that the results that they obtain through the new test are easier to read, allowing scientists to process thousands of tissue samples in one go. NG-CNA also has a quicker turnaround time for the results, at approximately 36 hours. Finally, NG-CNA calls for the collection of smaller samples than other tests currently in use. The sample size can be as low as 12.5 ng of material, which would allow specialists to use the test to analyze cell lines, biopsy samples, and surgical samples.

Harry Ostrer, MD, a medical geneticist and lead author of the study said, “We have demonstrated that CNAs can be detected rapidly and accurately with the new Next-Generation Copy Number Alteration (NG-CNA) assay. We believe the addition of the NG-CNA assay onto a standard cancer gene testing platform will augment personalized medicine by identifying aggressive tumors and genetic mutations that are predictors of response to targeted therapies.” The study was published on December 12, 2018, in The Journal of Molecular Diagnostics.

Related Links:
Albert Einstein College of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.